MEI PHARMA INC (MEIP) Stock Price, Quote, News and Overview
NASDAQ:MEIP - Nasdaq - US55279B3015 - Common Stock - Currency: USD
MEIP Quote, Performance and Key Statistics
NASDAQ:MEIP (5/12/2025, 5:59:25 PM)
2.09
+0.04 (+2.2%)
The current stock price of MEIP is 2.09 USD. In the past month the price increased by 11.76%. In the past year, price decreased by -33.65%.
MEIP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.51 | 336.23B | ||
| AMGN | AMGEN INC | 13.24 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 13.41 | 129.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.99 | 62.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.15B | ||
| ARGX | ARGENX SE - ADR | 95.55 | 34.25B | ||
| ONC | BEIGENE LTD-ADR | 5.82 | 25.14B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.38B | ||
| NTRA | NATERA INC | N/A | 21.38B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.76B | ||
| BIIB | BIOGEN INC | 7.86 | 18.23B |
Related stock screener links
About MEIP
Company Profile
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2003-12-18. The Company’s pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor. Voruciclib has completed a Phase I trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as Venclexta). Voruciclib is also being evaluated in pre-clinical studies to explore potential activity in various solid tumor cancers including in combination with therapies that target the RAS signaling pathway, such as KRAS inhibitors. CDK9 has functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: myeloid leukemia cell differentiation protein (MCL1) and the MYC proto-oncogene protein (MYC) which regulates cell proliferation and growth.
Company Info
MEI PHARMA INC
11455 El Camino Real, Suite 250
San Diego CALIFORNIA 92130 US
CEO: Daniel P. Gold
Employees: 28
Phone: 18583697100
MEI PHARMA INC / MEIP FAQ
What is the stock price of MEI PHARMA INC today?
The current stock price of MEIP is 2.09 USD. The price increased by 2.2% in the last trading session.
What is the ticker symbol for MEI PHARMA INC stock?
The exchange symbol of MEI PHARMA INC is MEIP and it is listed on the Nasdaq exchange.
On which exchange is MEIP stock listed?
MEIP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MEI PHARMA INC stock?
6 analysts have analysed MEIP and the average price target is 6.12 USD. This implies a price increase of 192.82% is expected in the next year compared to the current price of 2.09. Check the MEI PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEI PHARMA INC worth?
MEI PHARMA INC (MEIP) has a market capitalization of 13.92M USD. This makes MEIP a Nano Cap stock.
How many employees does MEI PHARMA INC have?
MEI PHARMA INC (MEIP) currently has 28 employees.
What are the support and resistance levels for MEI PHARMA INC (MEIP) stock?
MEI PHARMA INC (MEIP) has a support level at 2.07 and a resistance level at 2.16. Check the full technical report for a detailed analysis of MEIP support and resistance levels.
Is MEI PHARMA INC (MEIP) expected to grow?
The Revenue of MEI PHARMA INC (MEIP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the MEIP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MEI PHARMA INC (MEIP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MEIP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MEIP, evaluating the profitability, health, valuation and growth aspects
- MEI PHARMA INC (MEIP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEI PHARMA INC (MEIP) Sales and EPS estimates to see what analysts future expectations are.
- MEI PHARMA INC (MEIP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEI PHARMA INC (MEIP) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEI PHARMA INC (MEIP) Stock Chart to make your own analysis
- MEI PHARMA INC (MEIP) Latest news and press-releases to stay up to date.
Does MEI PHARMA INC (MEIP) stock pay dividends?
MEIP does not pay a dividend.
When does MEI PHARMA INC (MEIP) report earnings?
MEI PHARMA INC (MEIP) will report earnings on 2025-09-17, after the market close.
What is the Price/Earnings (PE) ratio of MEI PHARMA INC (MEIP)?
The PE ratio for MEI PHARMA INC (MEIP) is 0.78. This is based on the reported non-GAAP earnings per share of 2.67 and the current share price of 2.09 USD. Check the full fundamental report for a full analysis of the valuation metrics for MEIP.
What is the Short Interest ratio of MEI PHARMA INC (MEIP) stock?
The outstanding short interest for MEI PHARMA INC (MEIP) is 0.07% of its float. Check the ownership tab for more information on the MEIP short interest.
MEIP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MEIP. When comparing the yearly performance of all stocks, MEIP is a bad performer in the overall market: 85.09% of all stocks are doing better.
MEIP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MEIP. MEIP has a great financial health rating, but its profitability evaluates not so good.
MEIP Financial Highlights
Over the last trailing twelve months MEIP reported a non-GAAP Earnings per Share(EPS) of 2.67. The EPS increased by 157.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -156.72% | ||
| ROE | -172.94% | ||
| Debt/Equity | 0 |
MEIP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to MEIP. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -339.91% and a revenue growth -100% for MEIP